ESC 365 - Discussant - Dyslipidaemias: current strategies and innovations

ESC Professional Premium Access

Discussant - Dyslipidaemias: current strategies and innovations

Session: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

Topic: Lipid-Lowering Agents

Event: ESC Congress 2025

Congress Presentation

Add to my library

9 more presentations in this session

The efficacy and safety of low-intensity statins for high bleeding risk patients after PCI in Asian populations

Speaker: Doctor Z. Zhang (Tianjin, CN)

Statin users have lower fatty acid oxidative metabolisms in muscle mitochondria and have a higher content of long-chain and medium-chain acylcarnitines in muscles.

Speaker: Doctor E. Bolsteina (Riga, LV)

The efficacy of tafolecimab in lipoprotein(a) reductions in hypercholesterolaemic patients: a pooled analysis of three phase 3 trials

Speaker: Ms H. Shen (Beijing, CN)

Efficacy and metabolic impact of combination therapy vs. high-intensity statin monotherapy: an exploratory analysis of the Save SAMS Trial

Speaker: Professor S. Hong (Seoul, KR)

VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C

Speaker: Doctor X. Liu (CH)

Access the full session

New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

Speakers: Doctor Z. Zhang, Doctor E. Bolsteina, Ms H. Shen, Professor S. Hong, Doctor X. Liu

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources